Physician profile
Jerry Reimer
NPI 1700867678
$10,888.66
in general payments reported to CMS, 2019-2025
52 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $791 · 2021: $1,755 · 2022: $2,265 · 2023: $1,796 · 2024: $1,685 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,175.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,051.54 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Otsuka America Pharmaceutical, INC. | $791.05 | 2020-2025 | Rexulti, Nuedexta |
| Amgen INC. | $747.69 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $637.29 | 2019-2023 | Trintellix |
| Lilly USA, LLC | $578.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $538.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $504.25 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $382.04 | 2019-2023 | |
| Daiichi Sankyo INC. | $351.53 | 2019-2024 | Injectafer |
| Pfizer INC. | $277.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $259.46 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $208.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $197.24 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $162.74 | 2022-2024 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Reimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.